ArticleJACC. Case reports2026
Giant Cell Arteritis as a Form of Pembrolizumab-Associated Vascular Toxicity.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the use of immune checkpoint inhibitors becomes more prevalent in cancer treatment, physicians should be aware of immune-related adverse events. Cardiovascular toxicity is of particular concern because of the risk of serious consequences, yet little is known about these immune-related adverse events including giant cell arteritis (GCA). CASE SUMMARY: A 68-year-old man complained of new-onset daily persistent headache and fever after pembrolizumab initiation for renal cell carcinoma. The patient was negative for vasculitis-associated autoantibodies and showed no significant findings on ultrasound or contrast-enhanced computed tomography. However, contrast-enhanced magnetic resonance imaging revealed gadolinium enhancement in both temporal arteries, and temporal artery biopsy showed findings consistent with GCA. Prednisolone was initiated immediately and dramatically improved the clinical symptoms, which prevented vision loss.
conclusionsThis case highlights the importance of considering GCA as a possible diagnosis in patients receiving immune checkpoint inhibitors therapy who report development of new headache.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.